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Perivascular stromal cells and vascular endothelial cells (ECs) regulate HSC maintenance in the BM of mice [1] [2] [3] . Deletion of nestin-expressing mesenchymal stromal cells (MSCs) has also been shown to decrease HSC content in the BM, which is associated with HSC mobilization 4 . Leptin receptor (Lepr)-and paired related homeobox 1 (Prx1)-expressing perivascular cells and nestin-expressing stromal cells have been postulated to represent overlapping perivascular populations which regulate HSC maintenance in vivo 5, 6 . Recently, maintenance of quiescent, long-term repopulating HSCs was suggested to be dependent on chondroitin sulfate proteoglycan 4 (Cspg4 + or NG2 + ) pericytes localized to the arteriolar vascular niche, which are distinct from Lepr-expressing peri-sinusoidal cells 7 . These studies have confirmed the importance of perivascular cells and vascular ECs in regulating HSC maintenance.
Expansion of the BM osteoblast population has been shown to amplify the HSC pool in vivo 8, 9 , and ganciclovir-inducible depletion of BM osteoblasts decreases phenotypic hematopoietic stem and progenitor cell content 10 . However, deletion of the genes encoding stem cell factor (SCF), the chemokine CXCL12 or N-cadherin in BM osteoblasts does not have effects on HSC content during homeostasis [1] [2] [3] 11 . Sp7 (Osx) is a transcription factor expressed by mesenchymal progenitor cells, which have been shown via lineage tracing to be osteolineage-restricted in the adult mouse 6, 12, 13 . In the fetal BM, Osx-expressing cells contribute to nascent bone tissues and transient stromal cells, whereas perinatally, Osx-expressing cells contribute to long-lived MSCs and osteolineage cells 6, 13 . Notably, deletion of Dicer1, which encodes an RNaseIII endonuclease, in Osx-expressing cells promotes myelodysplasia in mice, suggesting that aberrant function of Osx-expressing cells may contribute to the development of hematologic malignancy 14 . Deletion of CXCL12 from Osx-expressing cells was also shown to deplete B lymphoid progenitors in homeostasis, but no effect on HSC function was observed 3 .
Although genetic studies have provided insight into the function of BM niche cells in regulating hematopoiesis during homeostasis, important questions remain regarding the contributions of niche cells during stress or injury, as well as the effects of injury on nichemediated regulation of HSCs. We and others have recently demonstrated the essential role of BM ECs in regulating HSC regeneration following myelotoxicity [15] [16] [17] , and we identified two BM EC-derived paracrine factors, pleiotrophin (PTN) and EGF, as regulators of HSC regeneration in vivo 18, 19 . However, the functions of BM mesenchymal and osteolineage cells in regulating HSC regeneration remain less well understood. Here we directly tested the function of Osx-expressing BM cells in regulating hematopoietic regeneration following myelosuppression and discovered that Osx-expressing BM cells promote hematopoietic regeneration via secretion of Dkk1.
RESULTS

Deletion of Bak and Bax in Osx-expressing cells radioprotects the hematopoietic system
To test whether radioprotection of these cells would alter the hematopoietic response to irradiation, we used Cre-loxP technology to delete loxP-flanked (floxed; FL) genes encoding the pro-apoptotic factors Bak and Bax in Osx-expressing cells (from Sp7-Cre;Bak1 −/− ;Bax FL/− mice, hereafter referred to as Osx-Cre;Bak1 −/− ;Bax FL/− mice) 15, 20 . To determine the proportion of Osx-labeled cells that expressed Osx in 8-week-old mice, we used Sp7-Cherry (hereafter referred to as Osx-Cherry) reporter mice, because these mice have a stronger reporter signal than mice with a GFP reporter driven by Osx-Cre. In 8-week-old Osx-Cherry reporter mice, approximately 60% of Cherrylabeled BM cells expressed Osx, as measured by flow cytometry, whereas in 5-d-old mice, 83% of Cherry-labeled BM cells expressed Osx (Fig. 1a) . These results indicate that a subset of Osx-labeled BM cells lose Osx protein expression between birth and adulthood. Adult Osx-Cre;Bak1 −/− ;Bax FL/− mice showed no baseline differences in the frequency of Osx + BM cells, BM trabecular bone content, complete blood counts, HSC content or repopulating HSC function, as compared to those in Osx-Cre;Bak1 −/− ;Bax FL/+ control mice, which retain one wild-type allele of Bax ( Supplementary Fig. 1a-g ). Next we irradiated both strains of mice with 500 cGy total body irradiation (TBI) to assess the response of Osx-expressing BM cells and of hematopoietic stem and progenitor cells to injury. Osx-Cre;Bak1 −/− ;Bax FL/− mice maintained Osx + BM cells at day 3 after irradiation as compared to Osx-Cre;Bak1 −/− ;Bax FL/+ mice, which showed depletion of this population ( Fig. 1b and Supplementary Fig. 1h) . As compared to Osx-Cre;Bak1 −/− ;Bax FL/+ mice at day 7 after TBI, Osx-Cre;Bak1 −/− ; Bax FL/− mice displayed increased BM cellularity, increased numbers of c-kit + Sca-1 + lineage − (KSL) stem-progenitors, SLAM + KSL HSCs, colony-forming cells (CFCs), and peripheral blood (PB) white blood cells (WBCs), neutrophils and lymphocytes (Fig. 1c-f) . In competitive transplantation experiments, congenic Bl6.SJL mice transplanted with BM cells from Osx-Cre;Bak1 −/− ;Bax FL/− mice showed a significant increase in multilineage hematopoietic cell reconstitution in both primary and secondary transplanted mice, as compared to mice that were transplanted with BM from Osx-Cre;Bak1 −/− ;Bax FL/+ mice (Fig. 1g,h ). Taken together, these data suggest that the hematopoietic response to radiation injury is regulated by Osx-expressing BM cells and that deletion of the intrinsic pathway of apoptosis in these cells promotes radioprotection of the hematopoietic system. Fig. 2a) . Among these candidates, we focused on Dkk1, a Wnt inhibitor, because Dkk1 was previously shown to be expressed and secreted by osteolineage cells under the control of osterix 21 , although it has no established role in regulating hematopoietic regeneration. Furthermore, in preliminary screening experiments we found that Dkk1 promoted CFC recovery from BM KSL cells that were irradiated with 300 cGy in vitro, whereas two other candidates, tissue inhibitor of metalloproteinase 2 (Timp2) and the chemokine Ccl20 (also known as MIP-3a), had no effect (data not shown). ELISA confirmed that Osx-Cre;Bak1 −/− ; Bax FL/− mice contained significantly higher levels of Dkk1 protein in the BM than Osx-Cre;Bak1 −/− ;Bax FL/+ mice (Fig. 1i) (Fig. 1j and Supplementary Fig. 2b ). Moreover, we found that Osx + BM cells expressed significantly more Dkk1 than BM ECs in C57BL/6 mice, both at steady state and following TBI (Fig. 1k) . These results indicate that Osx + BM cells are the primary source of Dkk1 in both Osx-Cre;Bak1 −/− ;Bax FL/− and wild-type mice.
Dkk1 treatment accelerates hematopoietic regeneration in vitro and in vivo
We next sought to evaluate whether Dkk1 regulates hematopoietic regeneration following irradiation. First, we assessed the effect of Dkk1 on the function of non-irradiated HSCs in vitro and in vivo. Treatment of non-irradiated BM KSL cells with 500 ng/ml Dkk1 in medium supplemented with thrombopoietin (TPO), SCF and Flt-3 ligand had no effect on total cell expansion, KSL expansion or CFC content, as compared to cells treated with medium alone (Supplementary Fig. 3a,b) . However, systemic treatment of C57BL/6 mice with 10 µg Dkk1 subcutaneously every other day for 4 weeks caused a significant increase in the numbers of BM KSL cells, BM c-kit + lin − cells and BM CFCs, as well as in the PB neutrophil frequency, compared to saline-treated mice ( Supplementary Fig. 3c-e) . These data suggest that during homeostasis, Dkk1 promotes the in vivo expansion of the myeloid progenitor cell pool.
To evaluate the function of Dkk1 in regulating hematopoietic regeneration following irradiation, we irradiated BM KSL cells with 300 cGy and cultured them in cytokine-containing medium with or without 500 ng/ml Dkk1. Dkk1 treatment significantly increased the recovery of CFCs at day 7 of culture, as compared to treatment with cytokines alone (Fig. 2a) . Furthermore, mice that had been competitively transplanted with the progeny of irradiated, Dkk1-treated KSL cells showed a significant increase in multilineage engraftment of donor CD45.2 + cells over the course of 16 weeks after transplantation (Fig. 2b) . These results suggest that Dkk1 directly promotes the regeneration of HSCs capable of primary competitive repopulation following irradiation.
Because Dkk1 promotes the regeneration of irradiated hematopoietic stem and progenitor cells (HSPCs) in vitro, we next tested whether systemic administration of Dkk1 could accelerate hematopoietic regeneration in vivo following TBI. Adult C57BL/6 mice were irradiated with 800 cGy TBI and treated subcutaneously with 10 µg Dkk1 or saline every other day for 21 d, beginning at day 1 after TBI. Systemic administration of Dkk1 caused a greater than eightfold increase in Dkk1 levels in the BM of C57BL/6 mice within 1 h, as compared to untreated mice (Fig. 2c) . Dkk1 treatment increased the recovery of WBCs, neutrophil counts, platelets and BM cell counts at day 21 as compared to saline-treated mice (Fig. 2d,e) . Furthermore, the numbers of BM KSL cells and CFCs were significantly increased in Dkk1-treated mice as compared to those in saline-treated controls (Fig. 2f,g ). Notably, following 800 cGy TBI, only 4 of 15 (27%) C57BL/6 mice that had been treated with saline survived to day 30, as compared to 13 of 14 mice (93%) that had been treated with Dkk1, a nearly 350% increase in survival in response to Dkk1 treatment (P = 0.0004) (Fig. 2h) .
We also evaluated whether Dkk1 treatment could affect long-term hematopoiesis in mice following radiation exposure. Adult C57BL/6 mice were irradiated with 600 cGy TBI, treated with 10 µg Dkk1 every other day for 21 d and evaluated at 12 weeks after irradiation. As comparedto saline-treated controls, Dkk1-treated mice showed no differences in complete blood counts and BM cell counts, percentages of SLAM + KSL or KSL cells, or frequencies of BM myeloid cells, B cells or T cells (Supplementary Fig. 4a-c) . However, at 12 weeks following 600-cGy irradiation, saline-treated mice had substantially reduced numbers of BM CFCs as compared to irradiated, Dkk1-treated mice (Fig. 2i) . These data suggest that TBI causes a long-term decline in myeloid progenitor cell function and that short-term treatment with Dkk1 abrogates radiation-induced damage to this progenitor cell population.
Inhibition of Dkk1 abrogates hematopoietic regeneration following TBI Because systemic administration of Dkk1 augments hematopoietic regeneration and survival of mice following TBI, we next tested Dkk1 expression in VE-cadherin + BM ECs and Osx + BM cells in mice before (0 cGy; VE-cadherin + , n = 3 mice; Osx + , n = 4 mice) and 48 h after 500 cGy TBI (n = 6 mice/group). Dkk1 expression levels in all groups were normalized to that in VE-cadherin + BM ECs at 48 h. *P = 0.03 and **P = 0.003. Throughout, P values were derived by using a two-tailed Student's t-test.
whether endogenous Dkk1 is necessary for normal hematopoietic regeneration following TBI. We irradiated adult C57BL/6 mice with a sublethal TBI dose of 500 cGy and then administered 100 µg of a blocking Dkk1-specific antibody or an IgG control antibody every other day for 14 d. Anti-Dkk1 treatment significantly lowered Dkk1 levels in the BM at 24 h after treatment (Supplementary Fig. 5a ). At day 10 following irradiation, mice that were treated with anti-Dkk1 had a significant decrease in BM cell counts and in the numbers of PB WBCs, neutrophils, lymphocytes, KSL cells and CFCs, as compared to those in irradiated, IgG-treated mice (Fig. 3a-c and Supplementary  Fig. 5b) . Furthermore, treatment with anti-Dkk1 caused a significant decrease in the 30-d survival of irradiated mice (6 of 12 alive, 50%) as compared to irradiated controls (12 of 12, 100%; P = 0.006) (Fig. 3d) . Taken together, these results suggest that endogenous Dkk1 plays an important role in regulating hematopoietic regeneration and survival following myelosuppression. BM KSL cells that were treated with TPO, SCF and Flt-3 ligand (TSF)-containing medium (medium), with or without 500 ng/ml Dkk1 (n = 3 assays/ group). *P = 0.003. (b) Left, mean percentage of donor CD45.2 + cell engraftment levels in recipient CD45.1 + mice over time following competitive transplantation with the progeny of 1 × 10 4 irradiated (300 cGy) BM KSL cells that were cultured with or without 500 ng/ml Dkk1 for 7 d. *P = 0.01, *P = 0.03, *P = 0.03, *P = 0.01 for 4, 8, 12 and 16 weeks, respectively. Right, mean percentages of donor myeloid (*P = 0.02), B cell (*P = 0.01) and T cell (*P = 0.01) engraftment at 16 weeks in recipient mice (n = 17 mice/group). (c) Dkk1 concentrations in the BM of mice at baseline, following 500 cGy treatment, and at 1 h and 24 h following administration of 10 µg Dkk1 administration (BL6 non-irradiated (NI), n = 5 mice; BL6, n = 5 mice; Dkk1 (1 h), n = 6 mice; Dkk1 (24 h), n = 5 mice). *P < 0.001, **P < 0.001. (d) Scatter plots of PB WBCs (left), neutrophils (middle) and platelet (right) counts at day +21 from mice irradiated with 800 cGy and then treated with saline or Dkk1 (saline, n = 5 mice; Dkk1, n = 12 mice). *P = 0.008, *P = 0.02, *P = 0.01; by Mann-Whitney U test. (e) Left, representative images of H&E-stained femurs from saline-treated (left) and Dkk1-treated (middle) mice at day +21 following treatment with 800 cGy (40×; scale bars, 100 µm). Right, mean BM cell counts (n = 5 mice/group). *P = 0.02. (f) Left, representative FACS plots showing the percentage of BM KSL cells in saline-treated and Dkk1-treated mice at day +21 following treatment with 800 cGy TBI. Middle and right, the mean percentage of KSL cells (*P = 0.02) (middle) and KSL cell numbers (*P = 0.008) (right) (n = 5 mice/group). P values determined by Mann-Whitney U test. (g) Mean numbers of BM CFCs at day +21 following treatment with 800 cGy TBI (n = 6 assays/group). *P = 0.04. (h) Survival of saline-treated (4/15) or Dkk1-treated (13/14) mice following treatment with 800 cGy TBI (27% versus 93%; P = 0.0004 by log-rank test). (i) Mean numbers of CFCs in C57BL/6 mice at 12 weeks after 600 cGy TBI and treatment with 10 µg Dkk1 or saline, subcutaneously, every other day through day +21 (n = 5 assays/group). *P = 0. 001. Throughout, unless otherwise noted, P values were derived by using a two-tailed Student's t-test. mice showed no significant differences in hematologic profile or BM stem and progenitor cell content at baseline compared to that in Dkk1 +/+ mice ( Supplementary Fig. 6a-d) . However, at day 10 following 500-cGy TBI, Osx-Cre;Dkk1 FL/+ mice showed a significant decrease in the numbers of WBCs, neutrophils and lymphocytes, as compared to those in Dkk1 +/+ mice (Fig. 3e) . BM cell counts and the number of BM KSL cells, CFCs, BM myeloid cells, T cells and B cells were also decreased significantly in Osx-Cre;Dkk1 FL/+ mice as compared to those in Dkk1 +/+ mice (Fig. 3f-h and Supplementary  Fig. 6e ). These data suggest that endogenous Dkk1, produced by Osxlabeled BM cells, has a necessary role in regulating the hematopoietic response to irradiation.
Next we treated 500-cGy-irradiated Osx-Cre;Dkk1 FL/+ mice with 10 µg of Dkk1 every other day for 10 d to determine whether Dkk1 treatment could rescue the hematopoietic phenotype of these mice. Although Dkk1 treatment did not alter the complete blood counts or BM cell counts in Osx-Cre;Dkk1 FL/+ mice at day 10 after TBI, this treatment did significantly increase the numbers of BM KSL cells and BM CFCs, as compared to those in untreated mice (Fig. 3e-h) . These results provide evidence that Dkk1 deletion is responsible for the BM stem and progenitor cell abnormalities observed early after radiation injury in Osx-Cre;Dkk1 FL/+ mice.
Our initial analysis of Osx-Cre;Dkk1 FL/+ mice, in which the Cre protein was expressed from inception, did not allow for discrimination between the effects of Dkk1 deletion in Osx-expressing osteoprogenitors and those in Osx-expressing long-lived MSCs in the BM, which can persist into adulthood 6 . In Osx-Cre;Dkk1 FL/+ mice, expression of a tetracycline transactivator under the regulation of the osterix (Sp7) promoter controls the expression of a tetracycline response element (TRE)-controlled Cre fusion protein 22 , such that doxycycline (Dox) administration prevents Cre-mediated recombination in Osx-expressing cells (Dox-Off). To study the effects of Dkk1 deletion starting at 8 weeks of age and older, we treated Osx-Cre;Dkk1 FL/+ mice with Dox from inception to 8 weeks of age (hereafter referred to as 8-week-OsxCre;Dkk1 FL/+ mice). Irradiation of 8-week-Osx-Cre;Dkk1 FL/+ mice with 500 cGy TBI at 10 weeks of age caused a significant decrease in the numbers of PB WBCs, neutrophils and lymphocytes, as well as in BM cell counts and in the numbers of BM KSL cells and BM CFCs at day 10 following TBI, as compared to those in Osx-Cre;Dkk1 +/+ mice ( Fig. 3i-l) . The enhanced hematopoietic toxicity following TBI that was observed in 8-week-Osx-Cre;Dkk1 FL/+ mice was comparable to that observed in Osx-Cre;Dkk1 FL/+ mice bearing a Dkk1 deletion from inception, suggesting that BM osteoprogenitor cells are the primary source of Dkk1 in regulating hematopoietic regeneration. 
Dkk1 suppresses reactive oxygen species generation and p38-mediated senescence in irradiated HSCs
Ionizing radiation can cause hematopoietic injury via generation of reactive oxygen species (ROS) and induction of HSC senescence 23 . At 24 h following 300-cGy irradiation of cells in vitro, the levels of mitochondrial ROS increased substantially in BM CD34 − KSL cells, KSL cells and lineage-negative (lin − ) cells (Fig. 4a and Supplementary  Fig. 7a ). Treatment with 500 ng/ml Dkk1 suppressed radiationinduced mitochondrial ROS generation in each cell population ( Fig. 4a and Supplementary Fig. 7a ). In vivo, systemic Dkk1 treatment of C57BL/6 mice irradiated with 500 cGy TBI resulted in a significant decrease in the levels of mitochondrial ROS in BM CD34 − KSL cells Middle, mean levels of EGF in BM ECs in response to 500 ng/nl Dkk1 treatment (*P < 0.001; BMEC, n = 5 cultures; BMEC + Dkk1, n = 10 cultures). Right, mean levels of EGF in C57BL/6 mice over time following 500 cGy TBI and treatment with saline or 10 µg Dkk1 every other day through day +14 (n = 5 mice/group) (day +10, *P = 0.03; day +14, *P = 0.02). (h) Mean values for PB WBCs, neutrophils, BM cell counts and BM KSL cells at days +10 and +14 following 500 cGy TBI and treatment with saline or 10 µg Dkk1, with and without 10 µg/g erlotinib (n = 5 mice/group). WBCs: day +10, *P < 0.001;day +14, *P = 0.002; neutrophils: day +10, *P < 0.001; day +14, *P = 0.01; BM cell counts: day +14, *P = 0.02; BM KSL cells: day +14, *P = 0.01. Throughout, P values were derived by using a two-tailed Student's t-test.
at 24 h after irradiation (Supplementary Fig. 7b) . In vitro treatment with Wnt3a (a canonical Wnt agonist) or Wnt5a (a noncanonical Wnt ligand) did not significantly alter mitochondrial ROS levels in irradiated CD34 − KSL cells, KSL cells or lin − cells beyond the effects observed with radiation alone (Fig. 4a and Supplementary Fig. 7a ). Consistent with its effects on decreasing ROS levels in irradiated HSCs, Dkk1 treatment of BM CD34 − KSL cells increased CFC recovery in vitro (Supplementary Fig. 7c ). However, in the presence of a ROS scavenger, N-acetylcysteine (NAC), Dkk1 treatment did not increase CFC recovery from irradiated KSL cells, suggesting that Dkk1-mediated hematopoietic regeneration is dependent, at least in part, on suppression of ROS (Supplementary Fig. 7c ). Elevated ROS levels drive activation of p38 mitogen-activated protein kinase (MAPK), which mediates a cytokine release phenomenon associated with senescence 23, 24 . Irradiation significantly increased p38 phosphorylation in BM CD34 − KSL cells at 24 h after exposure, and this increase was significantly attenuated by Dkk1 treatment (Fig. 4b) .
Of note, Dkk1 treatment had more modest effects in reducing p38 phosphorylation in irradiated BM KSL and lin − cells ( Supplementary  Fig. 7e ). Dkk1 treatment also significantly reduced senescenceassociated β-galactosidase (SA-β-gal) levels in irradiated BM CD34 − KSL cells, KSL cells and lin − cells ( Fig. 4c and Supplementary  Fig. 7f ). In contrast, treatment with Wnt3a or Wnt5a had no significant effects on either p38 phosphorylation or SA-β-gal levels in irradiated BM CD34 − KSL cells (Fig. 4b,c) . In keeping with its observed effects on SA-β-gal levels, Dkk1 suppressed radiation-induced expression of the p16-encoding isoform of cyclin-dependent kinase inhibitor 2a (Cdkn2a; hereafter referred to as p16) in BM CD34 − KSL cells in vitro and attenuated p16 expression in BM KSL cells in mice that were irradiated with 500 cGy (Fig. 4d) . Dkk1 treatment also suppressed HSC apoptosis in irradiated BM KSL cells, as measured by caspase-3-caspase-7 activation (Supplementary Fig. 7g ).
Next we extended our analysis of the effects of Dkk1 on radiationinduced senescence of BM HSC and progenitor cell populations by evaluating the long-term effects of systemic Dkk1 treatment on irradiated mice. At 12 weeks following 600 cGy TBI, C57BL/6 mice showed an increased frequency of SA-β-gal + KSL cells, consistent with the idea that senescent BM stem and progenitor cells persist following radiation injury (Fig. 4e) . This observation is in accord with a recent study that demonstrated that TBI induces persistent senescence of HSCs and premature aging of the hematopoietic system 25 . Notably, mice that were treated with Dkk1 every other day through day 21 following TBI showed a significantly lower percentage of SA-β-gal + KSL cells at 12 weeks, as compared to untreated, irradiated mice (Fig. 4e) . Coupled with our observation that Dkk1 treatment led to an increase in BM CFCs at 12 weeks following irradiation (Fig. 2i) , these data suggest that short-term treatment with Dkk1 promotes longer-term recovery of hematopoietic progenitor cells following radiation injury.
Dkk1 inhibits Wnt pathway activation in irradiated HSCs
Dkk1 is a member of the Dkk family of secreted proteins that can inhibit Wnt signaling via binding and sequestration of the Wnt coreceptors, LRP5 and LRP6 26 . Using Axin2-LacZ reporter mice as previously described 27, 28 , we evaluated Wnt pathway activation in BM HSC and progenitor cell subsets in response to irradiation and Dkk1 treatment. Exposure of mice to 500 cGy TBI increased Wnt signaling in BM CD34 − KSL cells, KSL cells and lin − cells at 24 h after exposure (Fig. 4f) . This activation of Wnt signaling was suppressed by Dkk1 treatment in these cell populations at 24 h after irradiation, as measured by the percentage of Axin2 + cells and the mean fluorescence intensity (MFI) of the Axin2-lacZ signal (Fig. 4f and Supplementary  Fig. 8a ). Of note, Wnt pathway activation in response to irradiation seemed to be stronger in the BM CD34 − KSL cells and the KSL cells as compared to that in BM lin − cells (Fig. 4f) . As assessed by the percentage of Axin2 + cells, Dkk1-mediated suppression of Wnt signaling was comparable across the three cell populations, although MFI analysis suggested that Dkk1 had the strongest suppressive effect in BM KSL cells (Supplementary Fig. 8a ). Axin2 mRNA levels increased concordantly in BM KSL cells in mice at 24 h after 500 cGy TBI, and this increase in Axin2 mRNA was abrogated by Dkk1 treatment (Supplementary Fig. 8b) .
To determine the functional relevance of Wnt inhibition to Dkk1-mediated hematopoietic regeneration, we used a viral Cre-based approach to delete Ctnnb1, the gene encoding β-catenin, in BM KSL cells from Ctnnb1 FL/FL mice (Supplementary Fig. 9a ) 29 . At 96 h following 300 cGy irradiation in vitro, Dkk1 treatment decreased ROS generation in Ctnnb1 +/+ BM KSL cells but not in Ctnnb1 −/− KSL cells (Supplementary Fig. 9b) . Similarly, Dkk1 treatment increased CFC recovery at 96 h after irradiation from Ctnnb1 +/+ KSL cells but not from Ctnnb1 −/− KSL cells (Supplementary Fig. 9c ). These data suggest that Wnt pathway inhibition contributes, at least in part, to the early effects of Dkk1 on ROS generation and hematopoietic progenitor recovery.
Dkk1 promotes hematopoietic regeneration via induction of EGF secretion by BM ECs
Next we tested the possibility that there might be cross-talk between Dkk1 and pleiotrophin (PTN) or EGF, two vascular-niche-derived proteins that we have previously shown to be HSC regenerative factors 16, 18, 19 . We first tested whether treatment of primary BM osteolineage cells (Osx + osteocalcin + cells cultured from femur bone explants) with PTN or EGF could induce Dkk1 secretion. However, this was not observed in 7-d culture; indeed, EGF treatment significantly reduced Dkk1 secretion (Supplementary Fig. 10 ). Next we asked whether Dkk1 could induce the secretion of these paracrine factors by primary BM ECs, as BM ECs are known to regulate HSC regeneration 15, 17, 30, 31 . Although Dkk1 treatment did not induce the secretion of PTN by primary BM ECs, it induced a greater than 5,000-fold increase in EGF levels after 7 d, as compared to that in untreated BM ECs (Fig. 4g) . Systemic administration of Dkk1 to mice irradiated with 500 cGy caused a marked increase in EGF levels in the BM at days 10 and 14 following radiation (Fig. 4g) . To test the functional relevance of Dkk1-mediated induction of EGF secretion to hematopoietic regeneration, we orally administered 10 µg per g body weight of erlotinib, an EGF receptor antagonist, daily for 10 d to 500-cGyirradiated, Dkk1-treated mice. Erlotinib treatment abrogated Dkk1-mediated recovery of PB WBCs, neutrophils, BM cell counts and BM KSL cells at day 10 and day 14, as compared to that in mice treated with Dkk1 alone (Fig. 4h) . These results suggest that, in addition to its direct effects on hematopoietic cells, Dkk1 promotes hematopoietic regeneration via induction of EGF secretion by BM ECs.
DISCUSSION
The functions of BM osteolineage cells and MSCs in regulating HSC regeneration are incompletely understood 32, 33 . Here we demonstrate that deletion of a single allele of Dkk1 in Osx-expressing BM cells abrogates hematopoietic regeneration following irradiation. Inducible deletion of Dkk1 in Osx-expressing cells in >8-week-old mice caused a comparable defect in hematopoietic regeneration in response to TBI as observed in mice bearing deletion of Dkk1 from inceptionin Osx-expressing cells. These data suggest that BM osteoprogenitor cells, rather than long-lived MSCs, are the primary source of Dkk1 that regulates hematopoietic regeneration in adult mice.
In gain-of-function studies, systemic Dkk1 treatment accelerated hematopoietic regeneration and improved survival following lethal dose TBI. This marked improvement in survival may have been related to the augmented recovery of myeloid progenitor cells, which have been shown to mediate survival following lethal dose TBI 34 . Dkk1 treatment also directly promoted the regeneration of HSCs with competitive repopulating capacity following irradiation in vitro. In a prior study of Dkk1 transgenic mice by Fleming et al., overexpression of Dkk1 at steady state was associated with an increased frequency of HSCs capable of primary competitive repopulation, coupled with a deficiency in HSCs capable of serial transplantation 35 . In the current study, we examined the effects of Dkk1 treatment or Dkk1 deletion on the hematopoietic regenerative response to myelotoxic injury, whereas Fleming et al. described the hematopoietic effects of Dkk1 overexpression during homeostasis 35 . It is possible that Dkk1-mediated signaling has distinct effects on HSCs in the setting of stress versus homeostasis, as has been demonstrated for Notch signaling 36 . Furthermore, we found that Dkk1 treatment induces BM ECs to secrete EGF, a regenerative factor for HSCs 19 , an effect that likely also contributes to the differences in the results of our study as compared to the prior study by Fleming et al. 35 .
Ionizing radiation causes the generation of ROS in HSCs, and ROS accumulation contributes to radiation-induced HSC apoptosis and senescence 23, 37, 38 . ROS are also deleterious to short-and long-term HSC function and HSC self-renewal capacity 39, 40 . ROS promote HSC senescence via activation of p38 MAPK and p16 23, 24 . Conversely, FoxO proteins are essential for downregulating ROS levels in HSCs, and transfer of ROS via gap junctions containing gap junction protein alpha 1 (Gja1; also known as connexin-43) to BM stromal cells can mitigate ROS-mediated HSC senescence 39, 40 . Notably, ROS generation occurs during BM or cord blood collection in ambient air, and this was recently shown to be highly damaging to HSC yield and function 41 . Furthermore, high-dose irradiation has been shown to markedly increase pO 2 concentrations in HSC niches via BM vascular disruption 42 . These findings underscore the therapeutic importance of suppressing ROS after myelosuppressive injury and may explain, in part, the potency of Dkk1 administration in promoting the survival of lethally irradiated mice.
Canonical Wnt signaling has been shown to regulate the fate of HSCs, myeloid progenitors and T cell subsets in a dosage-dependent manner [26] [27] [28] 43 . Using Axin2-lacZ reporter mice, we observed that TBI rapidly induced Wnt pathway activation in HSCs and progenitor cells and that systemic treatment with Dkk1 suppressed this response. Dkk1 also suppressed ROS generation and HSC senescence in irradiated mice, concordant with inhibitory effects on Wnt signaling. These findings are consistent with recent studies suggesting that Dkk1 treatment suppresses ROS generation in nonhematopoietic tissues, as well as a report demonstrating that Wnt pathway activation promotes mitochondrial ROS generation and senescence in myoblasts and fibroblasts 44, 45 . However, in the hematopoietic system, several studies have suggested that activation of canonical Wnt signaling promotes HSC self-renewal [46] [47] [48] . A recent study by Lento et al. suggested that mice with deletion of Ctnnb1 in hematopoietic Vav + cells showed reduced hematopoietic progenitor cell recovery at day 14 following TBI 49 . Several factors may explain the different observations between our study and that of Lento et al. First, acute inhibition of Wnt signaling with Dkk1 in the first 72 h after irradiation may have different effects on HSC regeneration as compared to that in mice with deletion of Ctnnb1 from inception. Second, it is possible that Dkk1 mediates effects on hematopoietic regeneration via mechanisms that are independent from its inhibitory effects on canonical Wnt signaling, as observed in models of kidney epithelial repair and cardiogenesis 50, 51 . As we discovered, Dkk1 acts indirectly on BM ECs, yielding a marked increase in EGF secretion, which contributed to hematopoietic regeneration. In this regard, a recent study demonstrated that ECs express LRP6, a Dkk1 receptor, and that Dkk1 and Dkk2 may regulate angiogenesis 52 . Third, the dosage of canonical Wnt pathway activation has been demonstrated to substantially impact HSCs, progenitor cells and HSC differentiation 28, 53 , and high dose levels of Wnt pathway activation can result in decreased HSC repopulating capacity 54, 55 . Our data suggest that during the early period following radiation injury, strong induction of Wnt signaling in HSCs may be deleterious, whereas early inhibition of Wnt signaling is beneficial.
Canonical and noncanonical Wnt signaling have been shown to have discrete effects on hematopoiesis 56 . Wnt5a expression in HSCs increases with aging, causing a shift to noncanonical Wnt signaling and a decline in HSC function in older mice 57 . HSC senescence occurs over time in aged mice and is exacerbated by stress, including radiation exposure 23, 37 . Here we observed that acute radiation injury increased canonical Wnt pathway activation in HSCs and that treatment with Dkk1 suppressed this signaling, in association with repression of ROS generation and HSC senescence. However, treatment with Wnt5a did not exacerbate radiation-induced ROS generation or HSC senescence. We postulate that the effects of Wnt5a and noncanonical Wnt signaling during hematopoietic aging may be distinct from the effects of noncanonical or canonical Wnt signaling in the setting of acute injury.
Over the past decade, as the cellular composition of the HSC niche has been elucidated, important questions have emerged regarding the hierarchy of cellular niche components and the manner through which niche cells communicate during their orchestration of HSC maintenance and regeneration 58, 59 . Recent studies suggest that distinct BM ECs within arterial and sinusoidal blood vessels regulate HSC maintenance and activation 60 . Our results demonstrate that BM osteoprogenitors regulate hematopoietic regeneration via secretion of Dkk1, which promotes hematopoietic regeneration directly via inhibition of HSC senescence and indirectly via induction of EGF secretion by BM ECs. This latter mechanism provides a unique example of cross-talk between distinct niche cell types and highlights the importance of cooperative niche cell interactions in hematopoietic regeneration.
METHODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper. 
